查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930073

全球抗癲癇藥物市場：市場規模、市場佔有率、成長率、產業分析、依類型、應用和地區劃分的分析、未來預測（2026-2034）

Antiepileptic Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 112 Pages | 商品交期: 請詢問到貨日

價格

抗癲癇藥物 (AED) 市場成長因子

由於全球癲癇患者人數不斷增加、人們對神經系統疾病的認識不斷提高以及藥物研發的持續進步，全球抗癲癇藥物 (AED) 市場正經歷穩步增長。根據 Fortune Business Insights 預測，該市場規模預計將在 2025 年達到 178.2 億美元，從 2026 年的 185.7 億美元增長到 2034 年的 275.7 億美元，在預測期（2026-2034 年）內複合年增長率 (CAGR) 為 5.10%。

截至 2025 年，北美在全球 AED 市場佔主導地位，市佔率高達 48.40%。 高診斷率、強有力的醫療保險政策以及新癲癇藥物頻繁獲得監管部門批准，都為市場成長提供了支持。

市場驅動因素

癲癇以反覆發作、意識喪失和行為障礙為特徵，是世界上最常見的神經系統疾病之一。根據世界衛生組織（WHO，2023）統計，全球約有5,000萬人患有癲癇，其中約80%生活在中低收入國家（LMIC）。如此高的疾病負擔使得對有效、長期抗癲癇療法的需求龐大。

癲癇盛行率的不斷上升給醫療保健系統帶來了沉重的經濟負擔，促使各國政府和製藥公司致力於擴大治療的可近性。為此，市場參與者正專注於開發療效更佳、副作用更小的標靶藥物，這正積極推動市場成長。

新冠疫情的影響

新冠疫情對抗癲癇藥物（AED）市場產生了負面影響，主要原因是神經科門診就診量減少、藥品供應鏈中斷以及醫療服務獲取受限。然而，自2022年以來，神經科門診量已逐漸增加，處方量也呈現復甦趨勢。因此，預計該市場將在2026年至2034年間恢復到疫情前的成長軌道。

市場趨勢

對第三代抗癲癇藥物的關注度日益提高

影響市場的一個關鍵趨勢是，人們越來越關注旨在解決抗藥性和副作用等未滿足需求的第三代抗癲癇藥物。第二代藥物的專利到期為製藥公司開發創新療法和仿製藥提供了機會。

例如，衛材株式會社正積極拓展其癲癇藥物產品組合，推出Fycompa（吡崙帕奈）的新劑型，包括於2024年1月在日本獲批的注射劑型，旨在為無法耐受口服藥物的患者提供更多治療選擇。

市場成長驅動因素

核准藥物數量不斷增加

儘管目前市面上的抗癲癇藥物（AED）種類繁多，但仍有約三分之一的患者會出現抗藥性或不耐受，這促使生產商加大研發投入。美國食品藥物管理局（FDA）和加拿大衛生部等監管機構正在批准新的治療方法，並推動創新。

例如，2023年6月，XCOPRI（塞諾巴酯片）在加拿大獲準作為部分性發作癲癇的輔助治療藥物，從而促進了市場擴張。

政府支持

政府投資和教育活動正在加速市場成長。澳洲、印度和中國等國在癲癇管理方面的醫療保健支出，正在改善患者獲得藥物的途徑，並促進抗癲癇藥物（AEDs）在全球的普及。

限制因子

藥物供應短缺

限制市場成長的主要挑戰之一是抗癲癇藥物短缺，尤其是在歐洲。英國脫歐帶來的不確定性以及關於瑞士藥品儲備義務的討論正在擾亂供應鏈。藥品儲備和供應可能會對治療的連續性產生負面影響，並抑制市場擴張。

市場區隔分析

依藥物代數

  • 到2026年，第二代藥物將主導市場，佔39.87%的市場佔有率，這主要得益於Lyrica和Keppra等重磅藥物的推動。
  • 由於價格實惠且具有長期臨床應用價值，第一代藥物仍佔重要地位。
  • 由於治療範圍更廣、副作用更少，預計第三代藥物將實現最快的增長速度。

依分銷管道

  • 在先進的基礎設施和保險覆蓋的支持下，醫院藥局將在2026年佔50.70%的市場佔有率。
  • 由於就醫便利性和遠距醫療的普及，預計零售藥局和線上藥局將穩定成長。

區域概況

  • 北美：預計到 2025 年市場規模將達到 86.3 億美元，強勁的研發投入和教育計畫將推動成長。美國市場預計到 2026 年將達到 72.7 億美元。
  • 歐洲：儘管面臨供應挑戰，但監管批准的增加正在支撐成長。
  • 亞太地區：由於癲癇盛行率上升以及中國、印度和日本醫療保健服務的改善，該地區正在快速成長。
  • 拉丁美洲、中東和非洲：由於醫療保健基礎設施的改善，預計成長將較為溫和。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家和地區癲癇盛行率（2025 年）
  • 主要公司新產品發布
  • 產品線分析
  • 抗癲癇藥物市場面臨的挑戰：概述
  • 主要產業趨勢：併購與合作
  • 新冠疫情的影響市場

第五章 全球抗癲癇藥物 (AED) 市場分析：洞察與預測 (2021-2034)

  • 市場分析、洞察與預測：依藥物代數劃分
    • 第一代
    • 第二代
    • 第三代
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美抗癲癇藥物 (AED) 市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲抗癲癇藥物（AED）市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區抗癲癇藥物（AED）市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲抗癲癇藥物 (AED) 市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲抗癲癇藥物 (AED) 市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東其他地區非洲

第十一章 競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
    • Pfizer Inc.
    • UCB S.A.
    • GSK plc.
    • H. Lundbeck A/S
    • Eisai Co., Ltd.
    • Sanofi
    • Sunovion Pharmaceuticals Inc.
    • Jazz Pharmaceuticals, Inc.
Product Code: FBI101189

Growth Factors of antiepileptic drugs (AED) Market

The global antiepileptic drugs (AED) market is witnessing steady growth due to the rising prevalence of epilepsy worldwide, increasing awareness regarding neurological disorders, and continuous advancements in drug development. According to Fortune Business Insights, the market was valued at USD 17.82 billion in 2025 and is projected to grow from USD 18.57 billion in 2026 to USD 27.57 billion by 2034, registering a CAGR of 5.10% during the forecast period (2026-2034).

North America dominated the global AED market in 2025, accounting for a 48.40% market share, supported by higher diagnosis rates, strong reimbursement policies, and frequent regulatory approvals for novel epilepsy drugs.

Market Drivers

Epilepsy is one of the most prevalent neurological disorders globally, characterized by recurrent seizures, loss of consciousness, and behavioral disturbances. According to the World Health Organization (WHO, 2023), approximately 50 million people worldwide are affected by epilepsy, with nearly 80% residing in low- and middle-income countries (LMICs). This high disease burden creates a substantial demand for effective and long-term antiepileptic therapies.

The growing prevalence of epilepsy places a significant economic burden on healthcare systems, driving governments and pharmaceutical companies to expand access to treatment. In response, market players are focusing on developing target-specific drugs with improved efficacy and reduced side effects, which is positively influencing market growth.

Impact of COVID-19

The COVID-19 pandemic negatively impacted the AED market, primarily due to reduced patient visits to neurological clinics, disruptions in drug supply chains, and limited access to healthcare services. However, from 2022 onwards, neurological consultations gradually increased, restoring prescription volumes. As a result, the market is expected to regain its pre-pandemic growth trajectory during 2026-2034.

Market Trends

Rising Focus on Third-Generation Antiepileptic Drugs

A key trend shaping the market is the growing emphasis on third-generation antiepileptic drugs, designed to address unmet clinical needs such as drug resistance and adverse effects. Patent expirations of second-generation drugs have created opportunities for pharmaceutical companies to develop both innovative therapies and generics.

For instance, Eisai Co., Ltd. has actively expanded its epilepsy portfolio by launching new formulations of Fycompa (perampanel), including an injection formulation approved in January 2024 in Japan, enhancing treatment options for patients unable to take oral medications.

Market Growth Factors

Increasing Product Approvals

Despite the availability of numerous AEDs, nearly one-third of patients experience drug resistance or intolerability, prompting manufacturers to intensify R&D activities. Regulatory bodies such as the U.S. FDA and Health Canada have been approving new therapies, encouraging innovation.

For example, in June 2023, XCOPRI (cenobamate tablets) received regulatory approval in Canada for adjunctive treatment of partial-onset seizures, supporting market expansion.

Government Support

Government investments and awareness initiatives are accelerating market growth. Public healthcare expenditure on epilepsy management, as seen in countries like Australia, India, and China, is improving patient access to medications and driving adoption of AEDs globally.

Restraining Factors

Drug Supply Shortages

One of the major challenges restraining market growth is the shortage of antiepileptic drugs, particularly in Europe. Brexit-related uncertainties in the U.K. and mandatory drug reserve discussions in Switzerland have disrupted supply chains. Medicine stockpiling and limited availability can negatively affect treatment continuity, thereby restraining market expansion.

Segmentation Analysis

By Drug Generation

  • Second-generation drugs dominated the market in 2026, accounting for 39.87% share, driven by blockbuster drugs such as Lyrica and Keppra.
  • First-generation drugs maintained a notable presence due to affordability and long-term clinical use.
  • Third-generation drugs are expected to grow at the fastest rate due to broader therapeutic benefits and fewer adverse effects.

By Distribution Channel

  • Hospital pharmacies dominated the market in 2026 with a 50.70% share, supported by advanced infrastructure and reimbursement coverage.
  • Retail and online pharmacies are expected to grow steadily due to improved accessibility and telemedicine adoption.

Regional Insights

  • North America: Valued at USD 8.63 billion in 2025, driven by strong R&D investment and awareness programs. The U.S. market is projected to reach USD 7.27 billion by 2026.
  • Europe: Growth supported by increasing regulatory approvals despite supply challenges.
  • Asia Pacific: Fast-growing region due to rising epilepsy prevalence and improved healthcare access in China, India, and Japan.
  • Latin America & Middle East & Africa: Moderate growth driven by developing healthcare infrastructure.

Competitive Landscape

The market is highly consolidated, with key players including Pfizer Inc., UCB S.A., GSK plc., Eisai Co., Ltd., and Sanofi. While Pfizer's Lyrica has historically dominated the market, patent expiry has intensified competition from generics and newer therapies.

Conclusion

The global antiepileptic drugs (AED) market is set for steady growth through 2034, supported by rising epilepsy prevalence, continuous drug innovation, and favorable regulatory frameworks. With the market expected to reach USD 27.57 billion by 2034, sustained R&D investments, government support, and improved access to treatment will be critical in addressing unmet patient needs and driving long-term market expansion.

Segmentation By Drug Generation

  • First Generation
  • Second Generation
  • Third Generation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Generation, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Epilepsy, By Key Countries/ Regions, 2025
  • 4.2. New Product Launches, By Key Players
  • 4.3. Pipeline Analysis
  • 4.4. Overview of Challenges Faced in the Antiepileptic Drugs Market
  • 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.6. Impact of COVID-19 on the Market

5. Global Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Generation
    • 5.1.1. First Generation
    • 5.1.2. Second Generation
    • 5.1.3. Third Generation
  • 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.2.1. Hospital Pharmacies
    • 5.2.2. Retail Pharmacies
    • 5.2.3. Online Pharmacies
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Generation
    • 6.1.1. First Generation
    • 6.1.2. Second Generation
    • 6.1.3. Third Generation
  • 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.2.1. Hospital Pharmacies
    • 6.2.2. Retail Pharmacies
    • 6.2.3. Online Pharmacies
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Generation
    • 7.1.1. First Generation
    • 7.1.2. Second Generation
    • 7.1.3. Third Generation
  • 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.2.1. Hospital Pharmacies
    • 7.2.2. Retail Pharmacies
    • 7.2.3. Online Pharmacies
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Scandinavia
    • 7.3.7. Rest of Europe

8. Asia Pacific Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Generation
    • 8.1.1. First Generation
    • 8.1.2. Second Generation
    • 8.1.3. Third Generation
  • 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Retail Pharmacies
    • 8.2.3. Online Pharmacies
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.3.1. Japan
    • 8.3.2. China
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Southeast Asia
    • 8.3.6. Rest of Asia Pacific

9. Latin America Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Generation
    • 9.1.1. First Generation
    • 9.1.2. Second Generation
    • 9.1.3. Third Generation
  • 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.2.1. Hospital Pharmacies
    • 9.2.2. Retail Pharmacies
    • 9.2.3. Online Pharmacies
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Generation
    • 10.1.1. First Generation
    • 10.1.2. Second Generation
    • 10.1.3. Third Generation
  • 10.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.2.1. Hospital Pharmacies
    • 10.2.2. Retail Pharmacies
    • 10.2.3. Online Pharmacies
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. UCB S.A.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. GSK plc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. H. Lundbeck A/S
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Eisai Co., Ltd.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Sanofi
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Sunovion Pharmaceuticals Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Jazz Pharmaceuticals, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Drug Generation, 2021-2034
  • Table 2: Global Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 3: Global Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 4: North America Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Drug Generation, 2021-2034
  • Table 5: North America Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: North America Antiepileptic Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 7: Europe Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Drug Generation, 2021-2034
  • Table 8: Europe Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 9: Europe Antiepileptic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 10: Asia Pacific Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Drug Generation, 2021-2034
  • Table 11: Asia Pacific Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Asia Pacific Antiepileptic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Latin America Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Drug Generation, 2021-2034
  • Table 14: Latin America Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Latin America Antiepileptic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Middle East & Africa Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Drug Generation, 2021-2034
  • Table 17: Middle East & Africa Antiepileptic Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Middle East & Africa Antiepileptic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Antiepileptic Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Antiepileptic Drugs Market Value Share (%), by Drug Generation, 2025 & 2034
  • Figure 3: Global Antiepileptic Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 4: Global Antiepileptic Drugs Market Value (USD billion), by Region, 2025 & 2034
  • Figure 5: North America Antiepileptic Drugs Market Value (USD billion), by Drug Generation, 2025 & 2034
  • Figure 6: North America Antiepileptic Drugs Market Value Share (%), by Drug Generation, 2025
  • Figure 7: North America Antiepileptic Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 8: North America Antiepileptic Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 9: North America Antiepileptic Drugs Market Value (USD billion), By Country, 2025 & 2034
  • Figure 10: North America Antiepileptic Drugs Market Value Share (%), By Country, 2025
  • Figure 11: Europe Antiepileptic Drugs Market Value (USD billion), by Drug Generation, 2025 & 2034
  • Figure 12: Europe Antiepileptic Drugs Market Value Share (%), by Drug Generation, 2025
  • Figure 13: Europe Antiepileptic Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: Europe Antiepileptic Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: Europe Antiepileptic Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 16: Europe Antiepileptic Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 17: Asia Pacific Antiepileptic Drugs Market Value (USD billion), by Drug Generation, 2025 & 2034
  • Figure 18: Asia Pacific Antiepileptic Drugs Market Value Share (%), by Drug Generation, 2025
  • Figure 19: Asia Pacific Antiepileptic Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 20: Asia Pacific Antiepileptic Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: Asia Pacific Antiepileptic Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Antiepileptic Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Latin America Antiepileptic Drugs Market Value (USD billion), by Drug Generation, 2025 & 2034
  • Figure 24: Latin America Antiepileptic Drugs Market Value Share (%), by Drug Generation, 2025
  • Figure 25: Latin America Antiepileptic Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 26: Latin America Antiepileptic Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 27: Latin America Antiepileptic Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 28: Latin America Antiepileptic Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 29: Middle East & Africa Antiepileptic Drugs Market Value (USD billion), by Drug Generation, 2025 & 2034
  • Figure 30: Middle East & Africa Antiepileptic Drugs Market Value Share (%), by Drug Generation, 2025
  • Figure 31: Middle East & Africa Antiepileptic Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 32: Middle East & Africa Antiepileptic Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 33: Middle East & Africa Antiepileptic Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 34: Middle East & Africa Antiepileptic Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 35: Global Antiepileptic Drugs Market Share Analysis (%), By Company, 2025